Evidence map›Paper›PMID 35759210›Full record

ReviewCNS drugs2022

Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.

Andrew Lofts, Fahed Abu-Hijleh, Nicolette Rigg, Ram K Mishra, Todd Hoare

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in CNS drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrew LoftsSchool of Biomedical Engineering, McMaster University, 1280 Main Street, West Hamilton, ON, L8S 4L8, Canada.
Fahed Abu-HijlehDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main Street, West Hamilton, ON, L8S 4L8, Canada.
Nicolette RiggDepartment of Psychiatry and Behavioural Neurosciences, McMaster University, 1280 Main Street, West Hamilton, ON, L8S 4L8, Canada.
Ram K MishraSchool of Biomedical Engineering, McMaster University, 1280 Main Street, West Hamilton, ON, L8S 4L8, Canada.
Todd HoareSchool of Biomedical Engineering, McMaster University, 1280 Main Street, West Hamilton, ON, L8S 4L8, Canada. hoaretr@mcmaster.ca.ORCID 0000-0002-5698-8463

Funding

CIHR CPG-151963
6 · The paper itself

Abstract

While the intranasal administration of drugs to the brain has been gaining both research attention and regulatory success over the past several years, key fundamental and translational challenges remain to fully leveraging the promise of this drug delivery pathway for improving the treatment of various neurological and psychiatric illnesses. In response, this review highlights the current state of understanding of the nose-to-brain drug delivery pathway and how both biological and clinical barriers to drug transport using the pathway can been addressed, as illustrated by demonstrations of how currently approved intranasal sprays leverage these pathways to enable the design of successful therapies. Moving forward, aiming to better exploit the understanding of this fundamental pathway, we also outline the development of nanoparticle systems that show improvement in delivering approved drugs to the brain and how engineered nanoparticle formulations could aid in breakthroughs in terms of delivering emerging drugs and therapeutics while avoiding systemic adverse effects.

Indexed as

Mental DisordersAdministration, IntranasalBrainDrug Delivery SystemsHumansNosePharmaceutical PreparationsPharmaceutical Preparations

Identifiers

PMID35759210
PMCPMC9243954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.